CD274 and cancer: In view of their activity in different cancers, mAbs targeting PD-L1 (NCT02541604), or PD-1 (NCT02332668, NCT02304458) alone or combined with other mAbs (NCT02304458; NCT02914405), are also being tested in pediatric solid cancers, including relapsing Neuroblastoma (NB).